6 completed. 6 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 6 |
| Phase 1 | 4 | Completed 4 |
Follow Polypoidal Choroidal Vasculopathy: new trials by email Literature Review of Polypoidal Choroidal Vasculopathy trials Research Report on Polypoidal Choroidal Vasculopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) Avacincaptad Pegol - Idiopathic Polypoidal Choroidal Vasculopathy | Phase 2 | Completed | Ophthotech Corporation | 4 | 2015-03-12 | 2025-03-20 |
| Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy ranibizumab 0.5 or 2.0 mg/0.05 cc - Polypoidal Choroidal Vasculopathy | Phase 1 / Phase 2 | Completed | Southeast Retina Center, Georgia | 20 | 2011-09-01 | 2022-12-12 |
| Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2) high-dose ranibizumab, ranibizumab - PCV, Polypoidal Choroidal Vasculopathy | Phase 1 / Phase 2 | Completed | Hawaii Pacific Health | 24 | 2010-11-01 | 2017-10-09 |
| Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV) fosbretabulin, Saline - Polypoidal Choroidal Vasculopathy | Phase 2 | Completed | Mateon Therapeutics | 20 | 2009-07-01 | 2011-11-01 |
| Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy ranibizumab injection (0.5 mg) - Coats' Disease, Idiopathic Retinal Telangiectasia | Phase 1 / Phase 2 | Completed | Manhattan Eye, Ear & Throat Hospital | 18 | 2007-05-01 | 2012-10-25 |
| Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy ranibizumab 0.5 or 0.3 mg/0.05 cc - Polypoidal Choroidal Vasculopathy | Phase 1 / Phase 2 | Completed | Southeast Retina Center, Georgia | 20 | 2006-05-01 | 2019-04-16 |
Choroidal Neovascularization (2) · Myopia, Degenerative (1) · Pseudoxanthoma Elasticum (1) · Retinal Telangiectasis (1) · Vitelliform Macular Dystrophy (1) · von Hippel-Lindau Disease (1)
Choroid Diseases (6) · Eye Diseases (6) · Metaplasia (6) · Neovascularization, Pathologic (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Uveal Diseases (6) · Choroidal Neovascularization (4) · Abnormalities, Multiple (1) · Angiomatosis (1) · Cardiovascular Diseases (1) · Ciliopathies (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Connective Tissue Diseases (1)
Ranibizumab (5) · Bevacizumab (1) · Sodium Chloride (1) · aflibercept (1) · combretastatin (1) · fosbretabulin (1)
Southeast Retina Center, Georgia (2) · Hawaii Pacific Health (1) · Manhattan Eye, Ear & Throat Hospital (1) · Mateon Therapeutics (1) · Ophthotech Corporation (1)
United States (6) · Hong Kong (1) · Singapore (1) · South Korea (1) · Taiwan (1)
Dennis M. Marcus, M.D. (2) · Gregg T Kokame, MD, MMM (1) · Lawrence A. Yannuzzi, MD (1)